About CELG-RI Dividend Returns
Bristol-Myers Squibb Company Ce (CELG-RI) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of CELG-RI over the past year?
Bristol-Myers Squibb Company Ce (CELG-RI) delivered a total return of 166.94% over the past year when dividends are reinvested. The price-only return was 166.94%, meaning dividends contributed an additional 0.00 percentage points to total returns.
Q2How much would $10,000 invested in CELG-RI be worth today?
A $10,000 investment in Bristol-Myers Squibb Company Ce one year ago would be worth $26,694 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $26,694. Dividend reinvestment added $0 to the portfolio value.
Q3Does CELG-RI pay dividends?
Yes, Bristol-Myers Squibb Company Ce (CELG-RI) pays dividends. In the last year, CELG-RI paid approximately $2.40 per share in dividends (100.00% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.
Q4Did CELG-RI beat the S&P 500?
Yes, Bristol-Myers Squibb Company Ce (CELG-RI) outperformed the S&P 500 by 151.49 percentage points over the past year. CELG-RI delivered a total return of 166.94%, compared to the S&P 500's 15.45%. This 151.49pp alpha means investors in CELG-RI earned more than a passive S&P 500 index fund.
Q5What is CELG-RI's worst drawdown?
Bristol-Myers Squibb Company Ce (CELG-RI) experienced a maximum drawdown of -64.27% over the past year, declining from its peak on 2026-01-17 to its trough on 2026-01-30. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is CELG-RI's long-term total return over 10, 20, or 30 years?
Bristol-Myers Squibb Company Ce (CELG-RI) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is 230.9% (12.7% CAGR) — $10,000 would have grown to $33,090. Over 20 years: 230.9% total return (6.2% CAGR) — $10,000 → $33,090. Over 30 years: 230.9% total return (4.1% CAGR) — $10,000 → $33,090. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was CELG-RI's best and worst year?
Bristol-Myers Squibb Company Ce's best calendar year was 2022 with a total return of 43.7%. Its worst year was 2023 with a total return of -26.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 69.9 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).